AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22952178 — intervention group
Group type: EXPERIMENTAL
Intervention: Leucine intake of 500 mg · kg⁻¹ · d⁻¹
Number of subjects: 5
Study 22952178 — intervention group
Group type: EXPERIMENTAL
Intervention: Leucine intake of 750 mg · kg⁻¹ · d⁻¹
Number of subjects: 5
Study 20723631 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumococcal polysaccharide vaccine (PPV)
Number of subjects: 786
Study 20723631 — intervention group
Group type: COMPARATOR
Intervention: Non-PPV group
Number of subjects: 786
Study 18275575 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib 200 mg orally 12 hourly for 24 hours
Number of subjects: 329
Study 18275575 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac 100 mg orally 12 hourly for 24 hours
Number of subjects: 329
Study 18275575 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib
Number of subjects: 329
Study 18275575 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac
Number of subjects: 329
Study 15891564 — intervention group
Group type: EXPERIMENTAL
Intervention: Diphtheria-tetanus vaccination
Number of subjects: 37
Study 15891564 — intervention group
Group type: EXPERIMENTAL
Intervention: Measles-mumps-rubella vaccination
Number of subjects: 37
Study 15891564 — intervention group
Group type: COMPARATOR
Intervention: Maintenance chemotherapy
Number of subjects: 37
Study 15891564 — intervention group
Group type: COMPARATOR
Intervention: Cessation of therapy (3-6 months)
Number of subjects: 37
Study 15891564 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 37
Study 12504699 — intervention group
Group type: EXPERIMENTAL
Intervention: Intacs microthin prescription inserts
Number of subjects: 26
Study 10800872 — intervention group
Group type: EXPERIMENTAL
Intervention: ZDV 100 mg tid + 200 mg nocte (ZDV-A)
Number of subjects: 204
Study 10800872 — intervention group
Group type: EXPERIMENTAL
Intervention: ZDV 250 mg bid (ZDV-B)
Number of subjects: 204
Study 10800872 — intervention group
Group type: COMPARATOR
Intervention: ZDV-A and ZDV-B
Number of subjects: 204
Study 8822458 — intervention group
Group type: EXPERIMENTAL
Intervention: MTX dissolved in saline solution (solution group)
Number of subjects: 26
Study 8822458 — intervention group
Group type: COMPARATOR
Intervention: MTX suspensions (suspension group)
Number of subjects: 26
Study 2250925 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-instructional booklet on pain control techniques (experimental group)
Number of subjects: 36
Study 2250925 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-instructional booklet on citizenship (placebo group)
Number of subjects: 36
Study 2250925 — intervention group
Group type: COMPARATOR
Intervention: Control group waited quietly for 13 min
Number of subjects: 36
Study 2250925 — intervention group
Group type: EXPERIMENTAL
Intervention: Warning periods of 5, 30, 60, and 180 sec
Number of subjects: 36
Study 6986940 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous intravenous infusion of morphine sulphate (3.5 times the pain-relieving dose, mean 36 mg)
Number of subjects: 45
Study 6986940 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular morphine sulphate (pain-relieving dose, mean 110 mg) administered four-hourly for the first 24 hours, six-hourly for the next 24 hours, and then eight and 20 hours later
Number of subjects: 45
Study 6986940 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular morphine sulphate (pain-relieving dose, mean 140 mg) as required
Number of subjects: 45
Study 29490082 — intervention group
Group type: EXPERIMENTAL
Intervention: Participant-interventionist bond at 4 weeks
Number of subjects: 398
Study 29490082 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherence (session attendance and online self-monitoring diary completion) at 6 months
Number of subjects: 398
Study 29490082 — intervention group
Group type: EXPERIMENTAL
Intervention: WAI-Bond subscale
Number of subjects: 398
Study 28146063 — intervention group
Group type: EXPERIMENTAL
Intervention: Two eggs per day
Number of subjects: 50
Study 28146063 — intervention group
Group type: COMPARATOR
Intervention: Oatmeal breakfast
Number of subjects: 50
Study 26076964 — intervention group
Group type: EXPERIMENTAL
Intervention: CHA2DS2‐VASc score
Number of subjects: 2010
Study 26076964 — intervention group
Group type: EXPERIMENTAL
Intervention: CHADS2 score
Number of subjects: 2010
Study 26076964 — intervention group
Group type: EXPERIMENTAL
Intervention: CHA2DS2‐VASc and CHADS2 scores
Number of subjects: 2010
Study 23800784 — intervention group
Group type: EXPERIMENTAL
Intervention: peg-interferon α‐2a at 180 μg/week
Number of subjects: 52
Study 23800784 — intervention group
Group type: COMPARATOR
Intervention: Control (observation)
Number of subjects: 52
Study 23800784 — intervention group
Group type: EXPERIMENTAL
Intervention: peg-interferon α‐2a
Number of subjects: 52
Study 21297523 — intervention group
Group type: EXPERIMENTAL
Intervention: GH 33 μg/kg/d
Number of subjects: 147
Study 21297523 — intervention group
Group type: EXPERIMENTAL
Intervention: GH 67 μg/kg/d
Number of subjects: 147
Study 21297523 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 147
Study 19031282 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV 16/18 vaccination
Number of subjects: 710
Study 17311807 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoxic exposure (10-15% O2)
Number of subjects: 10
Study 17311807 — intervention group
Group type: COMPARATOR
Intervention: Normoxic exposure (21% O2)
Number of subjects: 10
Study 15557357 — intervention group
Group type: EXPERIMENTAL
Intervention: Minilaparotomy cholecystectomy
Number of subjects: 724
Study 15557357 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic cholecystectomy (100 operations/year, reusable trocars)
Number of subjects: 724
Study 15557357 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic cholecystectomy (50 operations/year, disposable trocars)
Number of subjects: 724
Study 15557357 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic cholecystectomy
Number of subjects: 724
Study 11158001 — intervention group
Group type: EXPERIMENTAL
Intervention: PTH infusion (0.55 U/kg.h for 24 h) before GnRH agonist therapy
Number of subjects: 11
Study 11158001 — intervention group
Group type: EXPERIMENTAL
Intervention: PTH infusion (0.55 U/kg.h for 24 h) after 6 months of GnRH agonist therapy
Number of subjects: 11
Study 11158001 — intervention group
Group type: EXPERIMENTAL
Intervention: PTH infusion (0.55 U/kg.h for 24 h)
Number of subjects: 11
Study 9663722 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole (30 mg b.d.)
Number of subjects: 356
Study 9663722 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole (20 mg b.d.)
Number of subjects: 356
Study 7840513 — intervention group
Group type: EXPERIMENTAL
Intervention: Abrasio only (follow-up for 2 years)
Number of subjects: 368
Study 7840513 — intervention group
Group type: EXPERIMENTAL
Intervention: Abrasio only (follow-up for 5 years)
Number of subjects: 368
Study 7840513 — intervention group
Group type: EXPERIMENTAL
Intervention: Abrasio only (for patients with very severe atypia)
Number of subjects: 368
Study 7840513 — intervention group
Group type: EXPERIMENTAL
Intervention: Abrasio only (for another group of patients with atypical hyperplasia)
Number of subjects: 368
Study 7840513 — intervention group
Group type: EXPERIMENTAL
Intervention: Abrasio only (for other patients)
Number of subjects: 368
Study 3223435 — intervention group
Group type: COMPARATOR
Intervention: Ethanol (doses ranging from 0 to 1.05 g/kg lean body weight)
Number of subjects: 0
Study 29343448 — intervention group
Group type: EXPERIMENTAL
Intervention: 300‐mg ropivacain/600‐300‐300‐mg gabapentin (Group A)
Number of subjects: 128
Study 29343448 — intervention group
Group type: EXPERIMENTAL
Intervention: 150‐mg ropivacain/600‐300‐300‐mg gabapentin (Group B)
Number of subjects: 128
Study 29343448 — intervention group
Group type: EXPERIMENTAL
Intervention: 300‐mg ropivacain/300‐100‐100‐mg gabapentin (Group C)
Number of subjects: 128
Study 29343448 — intervention group
Group type: EXPERIMENTAL
Intervention: 150‐mg ropivacain/300‐100‐100‐mg gabapentin (Group D)
Number of subjects: 128
Study 27473584 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive film-based sexual-health intervention entitled If I Were Jack
Number of subjects: 800
Study 25019114 — intervention group
Group type: EXPERIMENTAL
Intervention: nano-hydroxyapatite 15% toothpaste
Number of subjects: 105
Study 25019114 — intervention group
Group type: COMPARATOR
Intervention: fluoride toothpaste
Number of subjects: 105
Study 25019114 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 105
Study 23052518 — intervention group
Group type: EXPERIMENTAL
Intervention: Kumar clamp
Number of subjects: 59
Study 23052518 — intervention group
Group type: COMPARATOR
Intervention: Olsen clamp
Number of subjects: 59
Study 20627268 — intervention group
Group type: EXPERIMENTAL
Intervention: computerized cognitive-behavioral therapy (cCBT)
Number of subjects: 100
Study 20627268 — intervention group
Group type: COMPARATOR
Intervention: waiting list control
Number of subjects: 100
Study 20627268 — intervention group
Group type: COMPARATOR
Intervention: in-person CBT
Number of subjects: 100
Study 18361267 — intervention group
Group type: EXPERIMENTAL
Intervention: Lymph drainage performed four or five times per week for 30 days
Number of subjects: 25
Study 18361267 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group B) received a type of massage for the same period and at the same frequency
Number of subjects: 25
Study 16964830 — intervention group
Group type: EXPERIMENTAL
Intervention: Amdoxovir (300 mg orally, twice daily)
Number of subjects: 18
Study 16964830 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 14576731 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-transplant minimal residual disease (MRD) level
Number of subjects: 31
Study 14576731 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-transplant minimal residual disease (MRD) status
Number of subjects: 31
Study 14576731 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential MRD monitoring post-ASCT
Number of subjects: 31
Study 10990114 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin-bonded central venous lines (HB CVLs)
Number of subjects: 209
Study 10990114 — intervention group
Group type: COMPARATOR
Intervention: Non-heparin-bonded central venous lines (NHB CVLs)
Number of subjects: 209
Study 9013400 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol (HAL)
Number of subjects: 15
Study 9013400 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol + Biperidene (HAL + BIP)
Number of subjects: 15
Study 1550145 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral erythromycin 333 mg every 8 hours from randomization to delivery
Number of subjects: 220
Study 1550145 — intervention group
Group type: COMPARATOR
Intervention: Indistinguishable placebo
Number of subjects: 220
Study 3902238 — intervention group
Group type: EXPERIMENTAL
Intervention: mianserin (30 mg/day for the first week, then doubled for the next three weeks)
Number of subjects: 62
Study 3902238 — intervention group
Group type: COMPARATOR
Intervention: maprotiline (75 mg/day for the first week, then doubled for the next three weeks)
Number of subjects: 62
Study 31246553 — intervention group
Group type: EXPERIMENTAL
Intervention: Text message notification
Number of subjects: 4947
Study 31246553 — intervention group
Group type: EXPERIMENTAL
Intervention: Cell phone call notification
Number of subjects: 4947
Study 31246553 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinic visit notification
Number of subjects: 4947
Study 31246553 — intervention group
Group type: EXPERIMENTAL
Intervention: Home visit notification
Number of subjects: 4947
Study 31246553 — intervention group
Group type: COMPARATOR
Intervention: Home visit
Number of subjects: 4947
Study 31246553 — intervention group
Group type: COMPARATOR
Intervention: Clinic visit
Number of subjects: 4947
Study 31246553 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall notification methods
Number of subjects: 4947
Study 28625540 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitting with breaks + high-energy diet
Number of subjects: 13
Study 28625540 — intervention group
Group type: COMPARATOR
Intervention: Uninterrupted sitting + high-energy diet
Number of subjects: 13
Study 28625540 — intervention group
Group type: COMPARATOR
Intervention: High-energy diet
Number of subjects: 13
Study 27165240 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly cisplatin 30 mg/m2 and paclitaxel 35 mg/m2 for 5‐6 weeks along with radiotherapy
Number of subjects: 25
Study 24858423 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal denervation
Number of subjects: 0
Study 24858423 — intervention group
Group type: COMPARATOR
Intervention: Sham control
Number of subjects: 0
Study 22610335 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine method (chisels)
Number of subjects: 300
Study 22610335 — intervention group
Group type: EXPERIMENTAL
Intervention: High speed turbine handpiece
Number of subjects: 300
Study 22610335 — intervention group
Group type: EXPERIMENTAL
Intervention: Piezosurgery device
Number of subjects: 300
Study 20301828 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided deep peroneal nerve block
Number of subjects: 18
Study 20301828 — intervention group
Group type: COMPARATOR
Intervention: Conventional landmark technique deep peroneal nerve block
Number of subjects: 18
Study 17583561 — intervention group
Group type: EXPERIMENTAL
Intervention: 18-gauge needle
Number of subjects: 42
Study 17583561 — intervention group
Group type: COMPARATOR
Intervention: 21-gauge needle
Number of subjects: 42
Study 15912390 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% aqueous and 0.1% hydrogel formulations of timolol
Number of subjects: 25
Study 12005083 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefepime
Number of subjects: 95
Study 12005083 — intervention group
Group type: COMPARATOR
Intervention: Ceftazidime
Number of subjects: 95
Study 9659094 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulse oximeter measurements
Number of subjects: 46
Study 9659094 — intervention group
Group type: COMPARATOR
Intervention: Oscillometric device measurements
Number of subjects: 46
Study 9659094 — intervention group
Group type: COMPARATOR
Intervention: Intra-arterial measurements
Number of subjects: 46
Study 7815679 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed-system containers (CS)
Number of subjects: 100
Study 7815679 — intervention group
Group type: COMPARATOR
Intervention: Open systems decanted from cans (OS-Can)
Number of subjects: 100
Study 7815679 — intervention group
Group type: COMPARATOR
Intervention: Open systems mixed from powder (OS-Powder)
Number of subjects: 100
Study 2550244 — intervention group
Group type: EXPERIMENTAL
Intervention: CGS 16617 50 mg/day
Number of subjects: 17
Study 2550244 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 2550244 — intervention group
Group type: EXPERIMENTAL
Intervention: Single ascending doses of CGS 16617 (20 to 100 mg)
Number of subjects: 17
Study 31758661 — intervention group
Group type: EXPERIMENTAL
Intervention: Ubrogepant (MK‐1602)
Number of subjects: 800
Study 31758661 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 800
Study 29970896 — intervention group
Group type: EXPERIMENTAL
Intervention: DEX
Number of subjects: 80
Study 29970896 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 28859672 — intervention group
Group type: EXPERIMENTAL
Intervention: Laquinimod (0.9 mg to 2.7 mg, escalating doses)
Number of subjects: 112
Study 28859672 — intervention group
Group type: EXPERIMENTAL
Intervention: Laquinimod
Number of subjects: 112
Study 28859672 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 112
Study 26338490 — intervention group
Group type: EXPERIMENTAL
Intervention: Coconut oil application (twice-daily)
Number of subjects: 74
Study 26338490 — intervention group
Group type: COMPARATOR
Intervention: Standard care (Control)
Number of subjects: 74
Study 23631607 — intervention group
Group type: EXPERIMENTAL
Intervention: Nateglinide (120 mg three times a day)
Number of subjects: 103
Study 23631607 — intervention group
Group type: EXPERIMENTAL
Intervention: Acarbose (50 mg three times a day)
Number of subjects: 103
Study 23631607 — intervention group
Group type: COMPARATOR
Intervention: Nateglinide and Acarbose (both treatments)
Number of subjects: 103
Study 20723033 — intervention group
Group type: EXPERIMENTAL
Intervention: Edoxaban 5 mg
Number of subjects: 523
Study 20723033 — intervention group
Group type: EXPERIMENTAL
Intervention: Edoxaban 15 mg
Number of subjects: 523
Study 20723033 — intervention group
Group type: EXPERIMENTAL
Intervention: Edoxaban 30 mg
Number of subjects: 523
Study 20723033 — intervention group
Group type: EXPERIMENTAL
Intervention: Edoxaban 60 mg
Number of subjects: 523
Study 20723033 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 523
Study 20723033 — intervention group
Group type: EXPERIMENTAL
Intervention: All Edoxaban doses
Number of subjects: 523
Study 19092465 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed combination of timolol maleate 0.5%/brimonidine tartrate 0.2%
Number of subjects: 210
Study 19092465 — intervention group
Group type: COMPARATOR
Intervention: Fixed combination of timolol maleate 0.5%/dorzolamide 2%
Number of subjects: 210
Study 17017227 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% suspension concentrate beta‐cypermethrin (double dose 2S at 100 mg AI/m2)
Number of subjects: 128
Study 17017227 — intervention group
Group type: COMPARATOR
Intervention: 5% suspension concentrate beta‐cypermethrin (standard dose S at 50 mg AI/m2)
Number of subjects: 128
Study 17017227 — intervention group
Group type: COMPARATOR
Intervention: 25% cypermethrin (CF at 100 mg AI/m2)
Number of subjects: 128
Study 17017227 — intervention group
Group type: COMPARATOR
Intervention: 10% permethrin (DF at 170 mg AI/m2)
Number of subjects: 128
Study 12818447 — intervention group
Group type: EXPERIMENTAL
Intervention: Tinidazole (T) 2g single dose + acidic vaginal gel (M) 2g every 3 days for 3 weeks
Number of subjects: 64
Study 12818447 — intervention group
Group type: COMPARATOR
Intervention: Vaginal clindamycin (CL) 2% for 7 days
Number of subjects: 64
Study 10902934 — intervention group
Group type: EXPERIMENTAL
Intervention: Countermeasure (CM) group (n = 4)
Number of subjects: 8
Study 10902934 — intervention group
Group type: COMPARATOR
Intervention: No-countermeasure (No-CM) group (n = 4)
Number of subjects: 8
Study 9162305 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat, high-dietary fiber, high-fruit and -vegetable eating pattern with dietary counseling
Number of subjects: 2079
Study 9162305 — intervention group
Group type: COMPARATOR
Intervention: Usual dietary intake without counseling
Number of subjects: 2079
Study 2000178 — intervention group
Group type: EXPERIMENTAL
Intervention: salmon calcitonin (sCT) 100 UI/day intermuscular for 4 weeks
Number of subjects: 20
Study 2000178 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 20
Study 6198368 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic oral and intravenous administration of kanamycin and metronidazole
Number of subjects: 0
Study 6198368 — intervention group
Group type: COMPARATOR
Intervention: Exclusion of kanamycin
Number of subjects: 0
Study 30699842 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutraceutical combination (S‐adenosyl methionine; Folinic acid; Omega‐3 fatty acids; 5‐HTP; Zinc picolinate)
Number of subjects: 158
Study 30699842 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 158
Study 28803178 — intervention group
Group type: EXPERIMENTAL
Intervention: SSIFL (short segment including fractured level)
Number of subjects: 74
Study 28803178 — intervention group
Group type: COMPARATOR
Intervention: LS (long segment)
Number of subjects: 74
Study 28803178 — intervention group
Group type: EXPERIMENTAL
Intervention: Fusion (in both groups)
Number of subjects: 74
Study 28803178 — intervention group
Group type: EXPERIMENTAL
Intervention: SSIFL
Number of subjects: 74
Study 28803178 — intervention group
Group type: COMPARATOR
Intervention: LS
Number of subjects: 74
Study 26654862 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfer within 1 hour after ICSI (Group A)
Number of subjects: 70
Study 26654862 — intervention group
Group type: COMPARATOR
Intervention: Transfer 3 days after ICSI (Group B, control group)
Number of subjects: 70
Study 25086208 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intervention
Number of subjects: 25
Study 22694045 — intervention group
Group type: EXPERIMENTAL
Intervention: Scaling and root planing (SRP) plus Nd:YAG laser (NDL) applications in nonsmoker patients (NST)
Number of subjects: 52
Study 22694045 — intervention group
Group type: COMPARATOR
Intervention: Scaling and root planing (SRP) in smoker patients (SP)
Number of subjects: 52
Study 22694045 — intervention group
Group type: COMPARATOR
Intervention: Scaling and root planing (SRP) plus Nd:YAG laser (NDL) applications in smoker patients (ST)
Number of subjects: 52
Study 22694045 — intervention group
Group type: COMPARATOR
Intervention: Scaling and root planing (SRP) in nonsmoker patients (NSP)
Number of subjects: 52
Study 19383806 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg dual-release hydrocortisone tablet
Number of subjects: 0
Study 19383806 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg dual-release hydrocortisone tablet after a high-calorie, high-fat meal
Number of subjects: 0
Study 19383806 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg dual-release hydrocortisone tablet
Number of subjects: 0
Study 16616048 — intervention group
Group type: EXPERIMENTAL
Intervention: Stop-signal frequency manipulation (less frequent stop signals)
Number of subjects: 0
Study 16616048 — intervention group
Group type: EXPERIMENTAL
Intervention: Stop-signal frequency manipulation (more frequent stop signals)
Number of subjects: 0
Study 12882848 — intervention group
Group type: EXPERIMENTAL
Intervention: Population management with direct physician feedback
Number of subjects: 149
Study 12882848 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 149
Study 10994544 — intervention group
Group type: EXPERIMENTAL
Intervention: Idarubicin (IDR) 14 mg/m2
Number of subjects: 17
Study 10994544 — intervention group
Group type: COMPARATOR
Intervention: Idarubicin (IDR) 12 mg/m2
Number of subjects: 17
Study 10994544 — intervention group
Group type: COMPARATOR
Intervention: Daunorubicin (DNR) 30 mg/m2
Number of subjects: 17
Study 8822745 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual stimulation (stroboscopic light)
Number of subjects: 6
Study 8822745 — intervention group
Group type: COMPARATOR
Intervention: Visual deprivation (blindfolded)
Number of subjects: 6
Study 1501561 — intervention group
Group type: EXPERIMENTAL
Intervention: Training at sea level at 70% maximal oxygen uptake (N = 7)
Number of subjects: 21